AGEN Agenus Inc

$AGEN Just stopped by the site to say “ Congrats” to you guys.. particularly to the long time holders whose monikers I recognize from the years reading the Yahoo message board. I first bought shares of Agenus back in 2016, but never joined Yahoo to post.. just read it religiously. Peter was the “ board master” so to speak for many years, but some of the posters now here on Stocktwits were there too. I traded in and out , actually missed the R/S , but still followed the stock. It took years and many trades to get back to even, but in July this year I saw daylight and moved on. Again, congrats to all the longs , particularly the ones in the stock as long or longer than I was. You folks deserve your success! I hope the stock keeps going higher! BTW, I’m certainly considering another position in old AGEN.. I’ve always thought the science was very good. Best Wishes!

$AGEN It will take a few days for the market to catch up to the news on Ovarian cancer survival. I think that 48%, 3 year survival is substantial news. Every time Dr. O'Day speaks, he says one thing, "We are seeing long survival tails", that is an indication that combo works. To me I see derisled stock for following reasons: - Continuing interest in bot/Bali with self pay and France reimbursement - Phase 3 is around the corner, and my assumption is that patient interest will be massive knowing that neo-adjuvant Bot/Bali is top of the line at the moment - Again there is a possibility that we get an AA next year either in US or Europe - Finally, there might be a bidding war to acquire Agenus once the Phase 3 is started Again, this is my personal opinion, everyone should do their own due diligence. Only other thing that I can say, that this has been a painful decade holding Agenus stock, but I think this time they are turning corner.

$AGEN been here for years. Almost $10 now per share. Another $10 for me to break even. And then hopefully finally going green!

$AGEN basically Dr. Kasi has proven to me that bot bal works. That’s why I own my shares.

$AGEN . Neoadjuvant BOT/BAL was safe and did not delay planned surgery in any patient. The major pathologic response rate was 41% (95% CI, 21%–64%) for pMMR, and 100% (95% CI, 40%–100%) for dMMR CRC

$AGEN 1. Major Oncology Medical Presentations (October & November 2026). Agenus has immediate clinical data milestones scheduled at prominent industry conferences: • ESMO Annual Congress (Oct 23–27, 2026): Presenting updated BOT+BAL trial progress. • SITC 2026 (Nov 4–8, 2026): Presenting highly anticipated long-term colorectal cancer survival data and ongoing translational research for their companion asset, agenT-797. 2. Corporate Earnings & Commercial Revenues (November 3, 2026) • Agenus will report its Q3 2026 financial earnings. • Why it matters: This will be the first glimpse at the early financial mechanics or upfront expansion numbers from their newly launched European access programs (like the early-access reimbursement framework in France) and their newly approved commercial rollout in Armenia. 3. Full Trial Publication Manuscripts (Late 2026)

$AGEN just look at the $KOD chart… proof that heavily diluted biotech stocks can fully reverse as long as the team executes and the drug brings positive results. We will see this above $100 by the end of next year. Congrats to the bulls. Congrats to I hope you all believers can retire soon off of this!

$AGEN Anyone that sees this news as being anytimg other than a positive should just sell or stop spewing nonsense on this MB. This stock simply isn’t for you. Sure the revenue we’ll be generating is practically insignificant but it also helps solidify how effective BOT/BAL is if nothing else. My next guess on approval, conditinal or otherwise will be Brazil. Just a hunch. GLTALS!

$AGEN .... Excellent news.... Merck suffers a setback in Europe over its new Keytruda formulation Ruling came as part of a widening patent infringement dispute over the cancer drug...

$AGEN this is really good news. Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer That shouldincrease our potential market cap significantly and in theory should convince the FDA to issue AA for two solid indications!

$AGEN There was a 102% change in Funds owning stock. They know something we don’t. Also I think this company is turning out to be positive. Determination goes a long way, it’s nice to see things start to turn around

$AGEN Rodman & Renshaw Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $19

$AGEN It is a platform with potential across several indications, and evidence continues to accumulate.

$AGEN Magic. I am not writing them off. I am invested heavily in $SMMT too. It’s just that ivo and Akeso’s PD-L1/CTLA4 bispexific are not competing wirh bot/bal. The trials are in MSI-H/dMMR colon cancer. Different animal.

$AGEN ... IMO..The reason we have an above average chance for AA in the 2nd half of 2027 is because of the neo-adjuvant trial itself. We won't have to wait years to see multiple MIRACULOUS results. This is where Bot/Bal will shine. It may take only some months for reports with similar pictures that our disbelieving eyes have already seen. Like the 40 yo lady had in what was it, 13 days? The tumor was GONE.... Not years later but in only days... I couldn't believe it.

$AGEN this $98.40 gap will eventually fill IMO. When we do get our first real big news such as major results, FDA approval, or buyout news the algos and day traders will inherently bring us to this level. Before it happens we should already be in the $20-$30 range. A 300%+ day euphoric move at that point is easily plausible with a low micro cap bio tech stock. We see it happen all the time. It’s not a matter of if not when. The fact that our pump on July 26th from $3.27 to $8.70 didn’t fully retrace and got bought up heavily and consolidated just tells me that people know something, more than average retail does. Still insanely undervalued here if what we all expect to play out does play out. It’s free to believe in something.

$AGEN I am not surprised that AGEN share price is going higher. I am also not surprised that Biotechguy21 doesn't post 23x per day.

$AGEN We are really close to a breakout to $12. AI says "Once it manages a clean breakout above the $8.76 – $8.85 window, technical indicators show a lack of immediate structural resistance directly above, creating a psychological runway toward double digits."

$AGEN Intresting timing on this Catalyst , All top brass locked and loaded the new board member got his stock and options then the $40 buy gets put out right after he is set up. I think we will see a strong 3 year update on or about the 1st. Get ready imo LEXINGTON, Mass., September 10, 2026--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

$AGEN On the latest episode of #OncologyUnplugged 🔌, host Chandler Park, M.D., F.A.C.P., of Norton Cancer Insitute, sits down with Pashtoon Kasi, MD, MS, of City of Hope Orange County, to discuss what may be one of the most significant paradigm shifts in CRC management: moving immunotherapy up front. Their conversation covers: 🔬 Why the high neoantigen load of dMMR/MSI-H tumors makes them so sensitive to checkpoint blockade 📊 The path from the phase 3 ATOMIC trial to the NICHE series, where a brief course of neoadjuvant nivolumab plus a single dose of ipilimumab produced near-universal responses 🧪 Dr Kasi's NEST trials of botensilimab plus balstilimab, which extended activity into the larger MSS population 🧬 Mechanistic insights, including an "inside-out" response pattern, regulatory T-cell depletion, and why an intact tumor and lymph nodes may matter ctDNA as an emerging surrogate end point, the STELLAR-303 data in MSS diseaseliver metastases as an immunosuppressive niche